Europe — EMA

Onglyza (Saxagliptin)

Saxagliptin, the active ingredient in Onglyza, is a DPP‑4 inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

Saxagliptin

Request sourcing

Pack/s

What is Saxagliptin?

Saxagliptin, the active ingredient in Onglyza, is a DPP‑4 inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Saxagliptin used for?

Onglyza is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, targeting the incretin pathway.

- Type 2 diabetes mellitus: Improves glycaemic control when combined with diet and exercise. - Adjunct therapy: Enhances blood‑sugar lowering effects of metformin or sulfonylureas. - Combination therapy : Provides a mult‑mult by

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →